The anti TNF Drugs (Humira, Remicade & Enbrel) for Rheumatic Disease have combined sales of more than US$ 30 Billion in 2015.
The Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022 report analyzes ongoing clinical and non-clinical trends in the global Tumor Necrosis Factor Inhibitors market. The anti TNF drugs are among the top 10 global block buster drugs and have dominated the global pharmaceutical market landscape for many years.
Over the past decade the pharmaceutical agents directed against TNF-a, infliximab, adalimumab and Etanercept, have been widely and successfully employed for the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, psoriatic arthritis, juvenile idiopathic arthritis and inflammatory bowel disease, and however two novel anti-TNF-a agents such as golimumab and certolimumab pegol, recently entered the market for the treatment of RA, AS, Crohn's disease and psoriasis.
The encouragement of the research by the positive results obtained from the use of TNF-a antagonists in terms of efficacy and safety and due to the increasingly collecting the evidence regarding the implication of TNF-a in the pathogenesis of numerous disorders and the anti-TNF-a agents have been considered for the management of diseases other than the ones they were initially approved for.
Anti-tumor necrosis factor (TNF) therapy is a valid, effective and increasingly used option in inflammatory bowel disease management. However, the further knowledge and therapeutic indications regarding the drugs are still growing. Anti-TNF therapy may be essential to achieve the recently projected end points and the prevention of bowel damage and prevention of patient's disability.
Anti-TNF drugs are also recommended to be more operative in early disease, particularly in early Crohn's disease. Moreover, its efficiency for prevention of postoperative recurrence in Crohn's disease is still debated. Costs and adverse effects, the significance of drug monitoring and the possibility of anti-TNF therapy withdrawal in selected patients are still debated issues. The reviews are expected to describe and discuss the most relevant data about the progress with anti-TNF therapy for the organization of inflammatory bowel disease.